----------Staff ScientistTargeted Analysis Group----------Bioanalytical Mass Spectrometry, Targeted Assay Development, Quantitative Analysis, and Organic Synthesis

----------Senior Research ScientistTargeted Analysis Group----------● Experience with bioanalytical chemistry and HPLC & LC/MS instrumentation and methodology which is used to analyze non-clinical samples for research studies and clinical samples for clinical trials (GCP). ● Synthesized reference materials and labeled internal standards to support research studies and clinical trials.

----------Senior Research ScientistMedicinal Chemistry - Lead Optimization----------● Designed and synthesized molecules for several lead series of antibiotics.● Took a lead role in the scale-up and purification of a preclinical antibiotic candidate molecule. ● Coordinated and drafted the tech-transfer documents for future chemical development.● Facilitated discussion with outside company to determine additional ways to evaluate risk in a preclinical candidate toxicology profile.

----------Principal Scientist, Oncology Research and DevelopmentMedicinal Chemistry - Lead Optimization----------● Member of the team which discovered the kinase inhibitor Dabrafenib (Tafinlar). This molecule was approved by the FDA in 2013 for patients with advanced/metastatic melanoma harboring a BRAF V600E mutation. ● Designed and synthesized molecules to support the lead optimization drug discovery effort. Key player on the team that optimized compounds for in-vitro and in-vivo investigations. ● Interacted with a multidisciplinary team consisting of scientists from the departments of chemistry, biology, computational chemistry, safety assessment, pharmacokinetics, and process development.● Led efforts for the synthesis of preclinical batches of Dabrafenib for safety assessment studies. ● Managed one associate scientist and a summer intern.● Recommended compound advancement based on safety and selectivity criteria from large in-vitro data sets. ● Led the safety team that enforced OSHA regulations and assessed safety inadequacies in the laboratories.----------Principal Scientist, Muscle Metabolism Center of Excellence in Drug DiscoveryMedicinal Chemistry - Lead Optimization----------● Synthesis of small molecules to support target validation for an Ion Channel blocker.● Synthesis of small-molecule agonists to to investigate an advanced program for a nuclear receptor.

Advisor: Michael T. Crimmins● Synthesized subunits for use in the total synthesis of psymberin (irciniastatin A), a potent cytotoxin from the marine sponge Psammocinia sp

● Involved with the synthesis and troubleshooting of clinical batches for drug candidates● Operated, set-up, and maintained kilo-lab and pilot plant equipment (12 L to 200 gal)● Gained experience with operating under cGMP protocol